MORF-057 is under clinical development by Morphic Therapeutic and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MORF-057’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MORF-057 overview

MORF-057 is under development for the treatment of autoimmune disorders including ulcerative colitis, Crohn's disease and eosinophilic esophagitis. It is administered orally. It is developed based on Morphic integrin technology (MInT). The drug candidate acts by targeting integrin alpha 4 and beta 7.

Morphic Therapeutic overview

Morphic Therapeutic Inc is a biotechnology firm. Oral integrin medicines are developed by the firm. The company is headquartered in United States.

For a complete picture of MORF-057’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.